Publications by authors named "C Kratochwil"
JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.
Eur J Nucl Med Mol Imaging
January 2025
Purpose: Prostate-specific membrane antigen (PSMA) radioligand therapy is a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Several beta or alpha particle-emitting radionuclide-conjugated small molecules have shown efficacy in late-stage mCRPC and one, [[177Lu]Lu]Lu-PSMA-617, is FDA approved. In addition to tumor upregulation, PSMA is also expressed in kidneys and salivary glands where specific uptake can cause dose-limiting xerostomia and potential for nephrotoxicity.
View Article and Find Full Text PDFArticle Synopsis
- Radiopharmaceutical therapies (RPTs) using fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) offer a new treatment option for patients with progressive metastatic cancers who have undergone multiple previous treatments.
- A study involving 6 patients with various types of metastatic solid tumors showed that fractionated Bi-FAPI-46 RPT was feasible and well tolerated, with no reported adverse effects.
- Initial results indicated mixed responses: one patient had a partial response, one had stable disease, while four experienced progressive disease, suggesting that while Bi-FAPI-46 RPT is promising, further research is needed to evaluate its effectiveness.
The aim of this work is to evaluate our clinical real-world data obtained with Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage prostate cancer. The objective parameters that could be derived from this evaluation are compared with previous literature about AcPSMA and Lu-PSMA-617 (LuPSMA). The medical files of all patients who had received AcPSMA on an individual patient basis at the Heidelberg University Hospital since January 2014 were analyzed retrospectively.
View Article and Find Full Text PDFThe development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of apalutamide.
View Article and Find Full Text PDF